U.S. markets closed

Inhibrx, Inc. (INBX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
18.26-0.22 (-1.19%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close18.48
Open18.36
Bid17.00 x 800
Ask24.67 x 1000
Day's Range17.13 - 18.42
52 Week Range15.20 - 50.97
Volume88,832
Avg. Volume152,522
Market Cap689.273M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est40.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Inhibrx Surpasses 4Q Revenue Estimates; Street Remains Bullish
      SmarterAnalyst

      Inhibrx Surpasses 4Q Revenue Estimates; Street Remains Bullish

      Inhibrx Inc posted better-than-expected 4Q revenue and also reported Phase 1 results for its therapeutic candidate, INBRX-105. The biotechnology company currently has four clinical development programs. Shares were up about 1.5% in Friday’s after-hours trading session. Inhibrx’s (INBX) revenue, mainly made up of license fees, increased to $2.78 million from $263,000 in the year-ago period and beat analysts’ estimates by $1.78 million. The company’s research and development expenses increased to $17.67 million from $12.28 million in the year-ago period. Despite this increase, Inhibrx’s net loss per share was $0.47 in 4Q, compared to a net loss per share of $0.90 in the prior-year quarter. This decrease was attributable to an increase in the company’s outstanding shares, which rose from about 18.15 million in 4Q19 to 37.7 million in 4Q. The company’s CEO Mark Lappe said, “2020 was a transformative year for Inhibrx. We made substantive advances in our four clinical programs across oncology and orphan disease, continued to progress our pre-clinical pipeline, and successfully completed an initial public offering.” (See Inhibrx stock analysis on TipRanks) Meanwhile, the Phase 1 study for Inhibrx’s INBRX-105 is being conducted in patients with locally advanced or metastatic solid tumors to evaluate the safety profile and determine the maximum tolerated dose of the drug. The company expects to begin enrollment for the Phase 2 study, a dose escalation study of INBRX-105 in combination with Keytruda, in 2Q and announce initial data in 4Q. Last month, Credit Suisse analyst Martin Auster raised the stock’s price target to $44 (87% upside potential) from $28 and reiterated a Buy rating. Auster sees “potential for significant program derisking if INBRX-101 can maintain plasma AAT levels within the normal range with evidence the drug effectively accesses the lung.” Further, “depending on the magnitude of de-risking observed and expectations of product positioning,” the analyst could see NPV upside of up to $20-$40 per share. The other analyst covering the stock, Jefferies’ Michael Yee, also reiterated a Buy rating. The two ratings add up to a Moderate Buy consensus rating alongside an average analyst price target of $47 (99.9% upside potential). Shares have rallied 37% over the past six months. Related News: Toll Brothers Bumps Up Quarterly Dividend By 54%; Street Says Hold Sun Communities Ramps Up Quarterly Dividend By 5%; Street Sees 14% Upside Qualcomm Bumps Up Quarterly Dividend By 5%; Street Sees 34% Upside More recent articles from Smarter Analyst: Alexco Resource Hit With Larger Quarterly Loss; Shares Slip 3% Sanofi, Translate Bio Kick Off Human COVID-19 Vaccine Trial; Shares Gain 5% Hill-Rom Ramps Up Quarterly Dividend By 9%; Shares Gain Novavax’s COVID-19 Vaccine Is 96.4% Effective In UK Trial; Shares Pop 23%

    • Inhibrx Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Announces Phase 1 Single Agent Dose Escalation Results for INBRX-105, a Novel Targeted 4-1BB Agonist
      PR Newswire

      Inhibrx Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Announces Phase 1 Single Agent Dose Escalation Results for INBRX-105, a Novel Targeted 4-1BB Agonist

      Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development, today reported financial results for the fourth quarter and fiscal year 2020, and announced results from the single agent dose escalation of the Phase 1 study of INBRX-105.

    • Inhibrx Announces Participation in Upcoming Investor Conference
      PR Newswire

      Inhibrx Announces Participation in Upcoming Investor Conference

      Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, announced today that the Company will be presenting at the following upcoming virtual investor conference: